China Medical System Holdings Limited (HKG:0867)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 27.45B +30.4% |
| Revenue (ttm) | 9.14B +9.9% |
| Net Income | 1.66B -8.1% |
| EPS | 0.68 -7.8% |
| Shares Out | 2.42B |
| PE Ratio | 16.56 |
| Forward PE | 11.71 |
| Dividend | 0.33 (2.85%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 1,136,113 |
| Average Volume | 4,252,958 |
| Open | 11.70 |
| Previous Close | 11.34 |
| Day's Range | 11.24 - 11.70 |
| 52-Week Range | 8.25 - 15.63 |
| Beta | 1.12 |
| RSI | 26.00 |
| Earnings Date | May 22, 2026 |
About HKG:0867
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Sal... [Read more]
Financial Performance
In 2025, HKG:0867's revenue was 8.21 billion, an increase of 9.95% compared to the previous year's 7.47 billion. Earnings were 1.49 billion, a decrease of -8.08%.
Financial numbers in CNY Financial StatementsNews
China Medical System reports NMPA acceptance of ruxolitinib phosphate cream NDA
China Medical System (CHSYF) Holdings announced that its subsidiary, Dermavon Holdings, received the acceptance from the National Medical Products Administration of China for the New Drug Application ...
China Medical says povorcitinib included in Breakthrough Therapeutic Drugs list
China Medical System (CHSYF) announced that its subsidiary, Dermavon Holdings has obtained the relevant licensing rights to the oral JAK1 inhibitor povorcitinib, which has been included in the list of...
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an i...
China Medical System announces NMPA acceptance of Y-3 NDA
China Medical System (CHSYF) announced that on 11 December 2025, the New Drug Application of Y-3 for Injection has been accepted by National Medical Products Administration of the People’s Republic…
China Medical System announces NMPA acceptance of MG-K10 NDA
China Medical System (CHSYF)s announced that its subsidiary, Dermavon Holdings, together with its subsidiaries, holds co-development rights and exclusive commercialization rights for the Class 1 drug ...
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®
SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VI...
China Medical announces Phase 3 ruxolitinib trial met primary endpoint
China Medical System (CHSYF) announces that its subsidiaries, Dermavon Holdings, obtained positive results from the phase 3 clinical trial of ruxolitinib cream in patients with mild to moderate atopic...
China Medical System announces NMPA acceptance of ZUNVEYL NDA
China Medical System (CHSYF) Holdings announced that on 28 July, the New Drug Application for improved new drug ZUNVEYL has been accepted by the National Medical Products Administration of China.
China Medical System enters collaboration agreement with Mabgeek Biotechnology
China Medical System (CHSYF) entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology and its subsidiary for Class 1 innovative drug anti-IL-4Ralpha humanized monoclonal antibody inject...
China Medical System gains exclusive commercialization right of ABP-671
China Medical System (CHSYF) entered into an Exclusive Commercialization Agreement with Atom Therapeutics of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia. In accordance ...